OrbiMed’s Verrica Pharmaceuticals VRCA Stock Holding History

OrbiMed’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-147,973	Closed	-$18.5M	–	177
2021 Q3	$18.5M	Hold	147,973	–	–	0.2%	99
2021 Q2	$16.7M	Hold	147,973	–	–	0.17%	103
2021 Q1	$22.4M	Hold	147,973	–	–	0.21%	95
2020 Q4	$17M	Hold	147,973	–	–	0.15%	105
2020 Q3	$11.5M	Hold	147,973	–	–	0.14%	107
2020 Q2	$16.3M	Hold	147,973	–	–	0.23%	83
2020 Q1	$16.2M	Hold	147,973	–	–	0.27%	76
2019 Q4	$23.5M	Hold	147,973	–	–	0.34%	61
2019 Q3	$21.8M	Hold	147,973	–	–	0.41%	58
2019 Q2	$17.2M	Hold	147,973	–	–	0.27%	76
2019 Q1	$16M	Hold	147,973	–	–	0.25%	82
2018 Q4	$12.1M	Hold	147,973	–	–	0.22%	83
2018 Q3	$24M	Hold	147,973	–	–	0.29%	79
2018 Q2	$29.2M	Buy	+147,973	New	+$29M	0.35%	68

Other funds holding VRCA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

OrbiMed's VRCA Position: Q4 2021 in Review

OrbiMed sold out of Verrica Pharmaceuticals (VRCA) in Q4 2021, closing a stake of 147,973 shares — an estimated $18.5M sold.

OrbiMed first reported a position in VRCA in Q2 2018 and held it in 14 quarters. The position peaked at $29.2M in Q2 2018. 45 funds tracked by Wall St. Rank hold VRCA as of Q4 2021.

OrbiMed reported no remaining Verrica Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
OrbiMed sold 147,973 Verrica Pharmaceuticals shares in Q4 2021, an estimated $18.5M.
OrbiMed first reported a position in Verrica Pharmaceuticals in Q2 2018 and held it in 14 quarters.
OrbiMed's Verrica Pharmaceuticals position peaked at $29.2M in Q2 2018.
45 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.